BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 18337683)

  • 41. Comparison of lesion-to-cerebellum uptake ratios and standardized uptake values in the evaluation of lung nodules with 18F-FDG PET.
    Obrzut S; Pham RH; Vera DR; Badran K; Hoha CK
    Nucl Med Commun; 2007 Jan; 28(1):7-13. PubMed ID: 17159543
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense?
    Hellwig D; Graeter TP; Ukena D; Groeschel A; Sybrecht GW; Schaefers HJ; Kirsch CM
    J Nucl Med; 2007 Nov; 48(11):1761-6. PubMed ID: 17942814
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
    Bian J; Yan K; Liu N; Xu X
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2621-2630. PubMed ID: 32661602
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differentiation of an adrenal mass in patients with non-small cell lung cancer by means of a normal range of adrenal standardized uptake values on FDG PET/CT.
    Kim BS; Lee JD; Kang WJ
    Ann Nucl Med; 2015 Apr; 29(3):276-83. PubMed ID: 25480483
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of positron emission tomography following radiosurgical treatment of malignant lung lesions.
    Gill BS; Rivandi AH; Sandhu SP; Jensen LG; Nobiensky PD; Hoh CK; Sandhu AP
    Nucl Med Commun; 2012 Jun; 33(6):607-12. PubMed ID: 22546820
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Significance of dual-time-point 18F-FDG PET imaging in evaluation of hilar and mediastinal lymph node metastasis in non-small-cell lung cancer].
    Hu M; Yu JM; Liu NB; Liu LP; Guo HB; Yang GR; Zhang PL; Xu XQ
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):306-9. PubMed ID: 18788639
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic value of 18-FDG uptake in early stage NSCLC.
    Chen JC; Huang TW; Cheng YL; Chang H; Tzao C; Huang WS; Lee SC
    Thorac Cardiovasc Surg; 2009 Oct; 57(7):413-6. PubMed ID: 19795329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients.
    van Baardwijk A; Bosmans G; Dekker A; van Kroonenburgh M; Boersma L; Wanders S; Ollers M; Houben R; Minken A; Lambin P; De Ruysscher D
    Radiother Oncol; 2007 Feb; 82(2):145-52. PubMed ID: 17258339
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.
    Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Dittmann H; Langen HJ; Bares R
    Lung Cancer; 2007 Feb; 55(2):165-71. PubMed ID: 17129635
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT.
    Sauter AW; Winterstein S; Spira D; Hetzel J; Schulze M; Mueller M; Pfannenberg C; Claussen CD; Klotz E; Hann von Weyhern C; Horger MS
    J Nucl Med; 2012 Apr; 53(4):521-9. PubMed ID: 22414637
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.
    Cherk MH; Foo SS; Poon AM; Knight SR; Murone C; Papenfuss AT; Sachinidis JI; Saunder TH; O'Keefe GJ; Scott AM
    J Nucl Med; 2006 Dec; 47(12):1921-6. PubMed ID: 17138734
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Leimgruber A; Möller A; Everitt SJ; Chabrot M; Ball DL; Solomon B; MacManus M; Hicks RJ
    J Nucl Med; 2014 Jul; 55(7):1075-80. PubMed ID: 24868108
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy.
    Imamura Y; Azuma K; Kurata S; Hattori S; Sasada T; Kinoshita T; Okamoto M; Kawayama T; Kaida H; Ishibashi M; Aizawa H
    Lung Cancer; 2011 Jan; 71(1):49-54. PubMed ID: 20430470
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer.
    Christensen JD; Colby TV; Patz EF
    Cancer; 2010 Sep; 116(17):4095-102. PubMed ID: 20533438
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
    Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
    Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of dual-time-point 18F-FDG-PET imaging for pulmonary lesions.
    Laffon E; de Clermont H; Begueret H; Vernejoux JM; Thumerel M; Marthan R; Ducassou D
    Nucl Med Commun; 2009 Jun; 30(6):455-61. PubMed ID: 19381115
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationship between primary lesion metabolic parameters and clinical stage in lung cancer.
    Sahiner I; Atasever T; Akdemir UO; Ozturk C; Memis L
    Rev Esp Med Nucl Imagen Mol; 2013; 32(6):357-63. PubMed ID: 23747221
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FDG PET-CT in non-small cell lung cancer: relationship between primary tumor FDG uptake and extensional or metastatic potential.
    Zhu SH; Zhang Y; Yu YH; Fu Z; Kong L; Han DL; Fu L; Yu JM; Li J
    Asian Pac J Cancer Prev; 2013; 14(5):2925-9. PubMed ID: 23803055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.